Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Blood (2024) 143 (16): 1616–1627.

https://doi.org/10.1182/blood.2023021959

Published: 2024

Includes: Supplemental data

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2023-186284

Published: 2023

Journal Articles

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Kerry A Rogers, Qiuhong Zhao, Seema A Bhat, John C. Byrd, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Gerard Lozanski, Margaret S. Lucas, Lindsey Rike, Shanmugapriya Thangavadivel, William E. Carson III, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 3272.

https://doi.org/10.1182/blood-2023-180308

Published: 2023

Journal Articles

Single-Cell RNA-Seq Analysis Reveals Distinct Tumor and Immunosuppressive T Cell Phenotypes in CLL Patients Treated with Ibrutinib

Shanmugapriya Thangavadivel, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Bradley Wayne Blaser

Blood (2023) 142 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2023-186604

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 497.

https://doi.org/10.1182/blood-2023-182114

Published: 2023

Journal Articles

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Nilanjan Ghosh, Ruibin Wang, Zhijie Ding, Jinghua He, Alex Bokun, Heena Mavani, Zaina P Qureshi, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 270.

https://doi.org/10.1182/blood-2023-187743

Published: 2023

Journal Articles

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood (2023) 142 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2023-173992

Published: 2023

Journal Articles

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Shanmugapriya Thangavadivel, Charlene Mao, Meixiao Long, Shrilekha Misra, Samon Benrashid, Britten Gordon, Alexander He, Tzung-Huei Lai, Kerry A Rogers, Seema A Bhat, Adam S Kittai, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2023-189755

Published: 2023

Journal Articles

Counting Chromosome Abnormalities in Chronic Lymphocytic Leukemia: Comparison of Iscn 2020 and MDS International Working Group Guidelines for Establishing Karyotype Complexity

Cecelia Miller, Ying Huang, Adam S Kittai, Seema A Bhat, Kerry A Rogers, Michael R. Grever, Jennifer A. Woyach, Matthew R Avenarius

Blood (2023) 142 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2023-180807

Published: 2023

Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Blood (2023) 142 (Supplement 1): 416.

https://doi.org/10.1182/blood-2023-178259

Published: 2023

Journal Articles

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 2260.

https://doi.org/10.1182/blood-2023-182024

Published: 2023

Journal Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 108.

https://doi.org/10.1182/blood-2023-180858

Published: 2023

Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach

Blood (2023) 142 (Supplement 1): 1899.

https://doi.org/10.1182/blood-2023-180294

Published: 2023

Journal Articles

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Seema A. Bhat, John Gambril, Leylah Azali, Sunnia T. Chen, Lindsay Rosen, Marilly Palettas, Tracy E. Wiczer, Sujay Kalathoor, Qiuhong Zhao, Kerry A. Rogers, Adam Kittai, Michael Grever, Farrukh Awan, Patrick Ruz, John C. Byrd, Jennifer Woyach, Daniel Addison

Blood (2022) 140 (20): 2142–2145.

https://doi.org/10.1182/blood.2022016953

Published: 2022

Includes: Supplemental data

Journal Articles

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Andrew Stiff, Qiuhong Zhao, Nilesh Kapoor, Kerry A. Rogers, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Gerard Lozanski, Michael R. Grever, Seema A. Bhat

Blood (2022) 140 (Supplement 1): 6524–6525.

https://doi.org/10.1182/blood-2022-166619

Published: 2022

Journal Articles

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A. Bhat, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Narendranath Epperla, Zeinab El Boghdadly, Michael R. Grever, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 9361–9362.

https://doi.org/10.1182/blood-2022-156720

Published: 2022

Journal Articles

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Blood (2022) 140 (Supplement 1): 9454–9456.

https://doi.org/10.1182/blood-2022-167651

Published: 2022

Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers

Blood (2022) 140 (Supplement 1): 4166–4168.

https://doi.org/10.1182/blood-2022-167314

Published: 2022

NARROW

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Single-Cell RNA-Seq Analysis Reveals Distinct Tumor and Immunosuppressive T Cell Phenotypes in CLL Patients Treated with Ibrutinib

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

T Cell Dysfunction and Exhaustion in Patients with CLL: The Impact of Long Term Ibrutinib Treatment

Counting Chromosome Abnormalities in Chronic Lymphocytic Leukemia: Comparison of Iscn 2020 and MDS International Working Group Guidelines for Establishing Karyotype Complexity

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

The PKC-β Inhibitor MS-553 Displays Preclinical Efficacy in BTK Inhibitor Resistant Chronic Lymphocytic Leukemia

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter's Transformation: An International Multicenter Retrospective Study

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only